Myovant Sciences CEO Creates Buzz At 2017 BIO CEO & Investor Conference

By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL

As host of the BIO Buzz Center during the 2017 BIO CEO & Investor Conference in New York City, Life Science Leader magazine had the opportunity to conduct five video interviews with a number of industry executives and thought leaders. One of these executives, Lynn Seely, M.D., is the president and CEO of Myovant Sciences (NYSE: MYOV). An industry veteran with over 20 years of drug development and biopharmaceutical leadership experience, Seely was appointed to leadership position in June 2016. Since taking the reins of Myovant Sciences (one of the companies developed by Roivant Sciences founder Vivek Ramaswamy), she has had to build a board, launch an IPO, which has the distinction of being the biggest biopharma IPO in 2016, as well as make preparations to initiate five phase three clinical trials (two being international clinical trials) for relugolix, an oral, once-daily, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist that decreases estrogen and progesterone. Below is my short video interview with Lynn Seely, president and CEO of Myovant Sciences.